Insider · CIK 0001816213
Yvonne McGrath
Files at ITOS (iTeos Therapeutics, Inc.). First filing -, latest -.
Yvonne McGrath files SEC Form 4 as officer at ITOS (iTeos Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Yvonne McGrath has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | UTender of shares Common Stock | -46,300 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -91,000 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -69,069 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,054 | - | - | 0 | Aug 29, 2025 |
Questions about Yvonne McGrath
Answered from the filings on this page, as of the latest one.
Is Yvonne McGrath buying or selling?
Yvonne McGrath has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Yvonne McGrath's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Yvonne McGrath has 0.
Where does Yvonne McGrath file Form 4?
Yvonne McGrath has filed Form 4 at ITOS (iTeos Therapeutics, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.